{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:55:03Z","timestamp":1781502903743,"version":"3.54.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, has demonstrated efficacy in inflammatory bowel disease (IBD). However, safety data in real-world Asian populations remain limited. This study aimed to characterize the adverse event (AE) profile of upadacitinib by integrating large-scale pharmacovigilance data with real-world clinical evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a dual-source analysis comprising spontaneous reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS; Q1 2018\u2013Q3 2025) and a retrospective single-center clinical cohort in China (April 2023\u2013September 2025). In the FAERS database, disproportionality analyses were performed using four algorithms (ROR, PRR, EBGM, and IC) to detect safety signals. In the clinical cohort, we assessed AE incidence, severity, timing, and management strategies. Subgroup analyses were descriptive, and Kaplan-Meier methods were used to estimate the time to the first AE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The clinical cohort included 183 patients, of whom 85 (46.4%) experienced at least one AE. The most common events were laboratory abnormalities, infections, and dermatologic conditions. Serious events, including intestinal perforation and venous thrombosis, were rare. A distinct early clustering of toxicity was observed: 38.8% of first events occurred within 30 days and 67.0% within 60 days of treatment initiation. Male reproductive safety appeared favorable; one patient experienced transient semen discoloration, which resolved following dose reduction. The FAERS analysis identified rare signals absent in the clinical cohort, notably Pneumocystis jirovecii pneumonia (PJP) and pseudostroke, highlighting potential high-risk scenarios. Signal classification revealed strong signals for herpes zoster and acne, moderate signals for venous thrombosis and laboratory abnormalities, and weak signals for rare events. AE patterns varied by age, disease type, and induction dose, consistent with the mechanistic expectations of JAK1 inhibition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Upadacitinib demonstrates a manageable safety profile in patients with IBD, with most AEs controllable through vigilant monitoring and individualized management. The integration of clinical cohort data with FAERS pharmacovigilance provides a comprehensive view of both common and rare risks. These findings offer critical real-world evidence from an Asian population, complementing global data to inform clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1830935","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:33:11Z","timestamp":1781501591000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety profile of upadacitinib in inflammatory Bowel disease: a dual-source pharmacovigilance study integrating FAERS signal detection and real-world clinical cohort analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Wei","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingya","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e70429","DOI":"10.1111\/cts.70429","article-title":"Janus kinase inhibitors during pregnancy and adverse drug reactions: a pharmacovigilance disproportionality analysis in VigiBase","volume":"18","author":"Abolhassani","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"B2","article-title":"Drug Safety in Developing Countries: Achievements and Challenges","author":"Al-Worafi","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"103276","DOI":"10.1016\/j.autrev.2023.103276","article-title":"JAK inhibitors and autoimmune rheumatic diseases","volume":"22","author":"Benucci","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cgh.2024.12.011","article-title":"AGA clinical practice update on noncolorectal cancer screening and vaccinations in patients with inflammatory bowel disease: expert review","volume":"23","author":"Caldera","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase II study","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/ibd\/izae091","article-title":"Pneumocystis jirovecii pneumonia complicating use of upadacitinib in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report","volume":"30","author":"Chin","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"B9","volume-title":"Rinvoq (Upadacitinib): Product Information. Annex I: Summary of Product Characteristics","year":"2019"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1683751","DOI":"10.3389\/fmed.2025.1683751","article-title":"Post-marketing surveillance of upadacitinib: multilevel analysis of venous thromboembolism reporting in global data and rheumatoid arthritis","volume":"12","author":"Ferreira-da-Silva","year":"2025","journal-title":"Front. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/1744666x.2023.2214728","article-title":"The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease","volume":"19","author":"Gupta","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B13","first-page":"1688","article-title":"Real-world effectiveness and safety of upadacitinib in patients with inflammatory bowel disease: a multicenter international cohort study","volume":"22","author":"Honap","year":"","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"","journal-title":"Frontline Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.cgh.2025.07.025","article-title":"Comparative effectiveness of tofacitinib vs upadacitinib for the treatment of acute severe ulcerative colitis","volume":"24","author":"Honap","year":"2026","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"A2119","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A2119","article-title":"Upadacitinib associated pneumocystis jirovecii pneumonia","volume":"203","author":"Jones","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-025-01097-1","article-title":"The global burden of inflammatory bowel disease: from 2025 to 2045","volume":"22","author":"Kaplan","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"jjaf231","DOI":"10.1093\/ecco-jcc\/jjaf231.1243","article-title":"Semen discolouration following upadacitinib therapy in patients with inflammatory bowel disease","volume":"20","author":"Lee","year":"2026","journal-title":"J. Crohn's Colitis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1672343","DOI":"10.3389\/fimmu.2025.1672343","article-title":"Risk of pulmonary fungal infections associated with biologics: a FAERS database disproportionality analysis","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/nejmoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/bcp.13329","article-title":"Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib","volume":"83","author":"Mohamed-Eslam","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B22","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults","volume":"74","author":"Moran","year":"2025","journal-title":"Gut."},{"key":"B23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2468-1253(25)00017-2","article-title":"Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study","volume":"10","author":"Panaccione","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2026.02.018","article-title":"Long-term safety of upadacitinib in patients with inflammatory bowel disease: integrated analysis of phase 2\/3 studies","author":"Panaccione","year":"2026","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"123917","DOI":"10.1016\/j.jchromb.2023.123917","article-title":"Development and validation of a multiplex HPLC-MS\/MS assay for the monitoring of JAK inhibitors in patient plasma","volume":"1230","author":"Tachet","year":"2023","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17512433.2025.2576698","article-title":"Therapeutic drug monitoring of Janus kinase inhibitors for precision dosing: where do we stand?","volume":"18","author":"Tachet","year":"2025","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B28","article-title":"Non-clinical review(s) for upadacitinib (NDA 211675)","year":"2019"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1699928","DOI":"10.3389\/fphar.2025.1699928","article-title":"Safety and efficacy of different JAK inhibitors in the treatment of inflammatory bowel disease: a network meta-analysis","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/nejmoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"111229","DOI":"10.1016\/j.intimp.2023.111229","article-title":"Effectiveness and safety of upadacitinib for inflammatory bowel disease: a systematic review and meta-analysis of RCT and real-world observational studies","volume":"126","author":"Zheng","year":"2024","journal-title":"Int. Immunopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1830935\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:33:13Z","timestamp":1781501593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1830935\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":31,"alternative-id":["10.3389\/fphar.2026.1830935"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1830935","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"1830935"}}